I was once interviewed live on Bloomberg radio at some god-awful hour in the morning, following a 30% drop in the share price of Ely Lily resulting from a negative decision in a patent case by the U.S. Court of Appeals in the District of Colombia. If you’d listened carefully, you could almost pick up the rasp of my unshaven face against the telephone receiver.

The news slot was aimed at brokers and bankers in the financial market. The interviewer was clearly keen for me to be some sort of soothsayer—to wring my hands and pronounce the forthcoming doom of Ely Lily, and of the pharma industry as a whole.

“Will this decision have an impact on pharma share prices here in the UK when the markets open?” he asked.

Please see full Letter below for more Information.

LOADING PDF: If there are any problems, click here to download the file.

Topics:  Eli Lilly, Jurisdiction, Patent Litigation, Patents, Pharmaceutical, Pharmaceutical Patents, Share Price, UK

Published In: Finance & Banking Updates, Intellectual Property Updates, Science, Computers & Technology Updates, Securities Updates

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Pillsbury Winthrop Shaw Pittman LLP | Attorney Advertising

Don't miss a thing! Build a custom news brief:

Read fresh new writing on compliance, cybersecurity, Dodd-Frank, whistleblowers, social media, hiring & firing, patent reform, the NLRB, Obamacare, the SEC…

…or whatever matters the most to you. Follow authors, firms, and topics on JD Supra.

Create your news brief now - it's free and easy »